Fair Value Calculator Fair Value Calculator
EN DE

8357 (8357) Fair Value & Analysis

Healthcare · Market cap HK$79.9M

8 8357 8357 · HK
PriceHK$0.1280
Fair ValueHK$0.0600
Upside-53.1%
Quality38/100
Watch 8357 for free — get notified when fair value or trend changes. Watch for free
Evidence: Low Range HK$0.0500 – HK$0.0900

Fair value as of: Jul 3, 2026

From 1 valuation models · updated today

Share price +25.5% over the past month.

Price vs Fair Value (12 months)

HK$0.2220 HK$0.0810 Fair Value HK$0.0600 Jun 2025 Jul 2026

12‑month range HK$0.0810 – HK$0.2220 · fair‑value band HK$0.0500 – HK$0.0900 · the HK$0.1280 price screens above the HK$0.0600 fair value. As of Jul 3, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

8357 (8357) currently trades at HK$0.1280, while our model-based Fair Value estimate is HK$0.0600 — implying the stock looks roughly 53.1% overvalued today. We read business quality at 38/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

Over the trailing twelve months, 8357 generated revenue of HK$8.1M at a net margin of -36.9%. Revenue declined 8.0% year over year. It earns a return on equity of -27.2%. The balance sheet holds a net cash position of HK$1.4M. Fundamentals as of Jul 3, 2026

Key figures & financial health

Revenue (TTM) HK$8.1M
Revenue growth (YoY) -8.0%
Net margin -36.9%
Return on equity -27.2%
Free cash flow −HK$3.1M FY2025
Operating margin -43.9%
More key figures
EPS growth (YoY) -100%
Net cash HK$1.4M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

8357 reported revenue of HK$7.8M in FY2025 versus HK$14.0M in FY2021, a compound −13.4%/yr. Reported net income was −HK$3.0M in FY2025.

Revenue −13.4%/yr
FY21 HK$14.0M
FY22 HK$9.4M
FY23 HK$10.3M
FY24 HK$9.2M
FY25 HK$7.8M
Net income
FY21 −HK$998K
FY22 −HK$1.5M
FY23 −HK$855K
FY24 −HK$178K
FY25 −HK$3.0M

Is 8357 fairly valued? → Check now

Similar stocks

6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).

Stock Price Fair Value vs Fair Value
HCA Healthcare, Inc H1CA34 R$95.75 R$123.65 +29%
Fresenius SE FSNUY $11.30 $8.61 -24%
5225 5225 8.67 MYR 3.08 MYR -64%
IHHHF IHHHF $1.71 $0.7400 -57%
Tenet Healthcare Corporation THC $162.06 $282.55 +74%
Rede D'Or São Luiz S.A RDOR3 R$32.76 R$30.33 -7%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is 8357 (8357) undervalued?
As of Jul 3, 2026, our model estimates a fair value of HK$0.0600 versus a price of HK$0.1280 — about −53% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 8357?
Our model-based fair value for 8357 is HK$0.0600 (as of Jul 3, 2026), built from audited fundamentals. The current price is HK$0.1280.
What is the quality score of 8357?
8357 has a Quality Score of 38/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of 8357 (8357)?
8357 reported trailing-twelve-month revenue of about HK$8.1M (latest available figure, as of Jul 3, 2026).
What is the net profit margin of 8357?
The net profit margin of 8357 is about -36.9%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.